deltatrials
Completed PHASE1 NCT01289080

Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects

A Single-dose, Open-label, Parallel-group, Matched Trial Evaluating the Pharmacokinetics of Oral OPC-34712 Tablets in Subjects With Normal Renal Function and Renally Impaired Subjects

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions Psychiatric Disorders Schizophrenia
Interventions OPC-34712
Updated 8 times since 2017 Last updated: Sep 29, 2015 Started: Jan 31, 2011 Primary completion: Dec 31, 2011 Completion: Jan 31, 2012

A PHASE1 clinical study on Psychiatric Disorders and Schizophrenia, this trial is completed. The trial is conducted by Otsuka Pharmaceutical Development & Commercialization, Inc. and has accumulated 8 data snapshots since 2011. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Otsuka Pharmaceutical Development & Commercialization, Inc.
Data source: Otsuka Pharmaceutical Development & Commercialization, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Miami, United States
  • • Minneapolis, United States